GYRE THERAPEUTICS, INC.

GYRE Therapeutics, Inc.

Biotechnology • Healthcare • San Diego, CA, United States • GYRE (NCM)

Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY, under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573 is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.

619 949 3681 12770 High Bluff Drive, San Diego, CA 92130, United States

Stock Performance (90 Days)

Data through Dec 29, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Gyre Therapeutics (NASDAQ:GYRE) Stock Price Down 3.6% - Time to Sell? - MarketBeat
MarketBeat • Dec 19
Is Gyre Therapeutics, Inc.'s (NASDAQ:GYRE) ROE Of 8.6% Concerning? - Yahoo Finance
Yahoo Finance • Nov 10
Behavioral Patterns of GYRE and Institutional Flows - Stock Traders Daily
Stock Traders Daily • Dec 25
Gyre Therapeutics Announces Completion of Patient - GlobeNewswire
GlobeNewswire • Oct 15
Gyre Therapeutics, Inc. (GYRE) Q3 Earnings Surpass Estimates - Nasdaq
Nasdaq • Nov 7

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has GYRE THERAPEUTICS, INC. had layoffs?
No layoff events have been recorded for GYRE THERAPEUTICS, INC. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does GYRE THERAPEUTICS, INC. have?
GYRE THERAPEUTICS, INC. has approximately 579 employees.
What industry is GYRE THERAPEUTICS, INC. in?
GYRE THERAPEUTICS, INC. operates in the Biotechnology industry, within the Healthcare sector.
Is GYRE THERAPEUTICS, INC. a publicly traded company?
Yes, GYRE THERAPEUTICS, INC. is publicly traded under the ticker symbol GYRE on the NCM. The company has a market capitalization of approximately $0.70 billion.
Where is GYRE THERAPEUTICS, INC. headquartered?
GYRE THERAPEUTICS, INC. is headquartered in San Diego, CA, United States at 12770 High Bluff Drive, San Diego, CA 92130, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.